The impact of preoperative systemic inflammation on the efficacy of intravenous iron infusion to correct anaemia prior to surgery for colorectal cancer

Stephen T. McSorley*, John H. Anderson, Thomas Whittle, Campbell S. Roxburgh, Paul G. Horgan, Donald C. McMillan and Colin W. Steele

Abstract

**Aim:** Intravenous iron is increasingly used prior to surgery for colorectal cancer (CRC) to correct iron deficiency anaemia and reduce blood transfusion. Its utility in functional iron deficiency (FID) or anaemia of inflammation is less clear. This observational study examined post-iron infusion changes in haemoglobin (Hb) based on grouping by C-reactive protein (CRP) and ferritin.

**Methods:** Anaemic (M:Hb < 130 mg/L, F:Hb < 120 mg/L) patients with CRC receiving iron infusion, within a preoperative anaemia detection and correction protocol, at a single centre between 2016 and 2019 were included. Patients were grouped by iron deficiency (ferritin < 30 μg/L and CRP ≤ 5 mg/L, n = 18), FID (ferritin < 30 μg/L and CRP > 5 mg/L, n = 17), anaemia of inflammation (ferritin ≥ 30 μg/L and CRP > 5 mg/L, n = 6), and anaemia of other causes (ferritin ≥ 30 μg/L and CRP ≤ 5 mg/L, n = 6). Median change in Hb and postoperative day (POD) 1 Hb was compared by Kruskal-Wallis test.

**Results:** Iron-deficient patients had the greatest increase in Hb after infusion (24 mg/L), highest POD 1 Hb (108 mg/L), and required no blood transfusions. Patients with FID had the second greatest increase in Hb (15 mg/L) and second highest POD 1 Hb (103 mg/L). Those with anaemia of inflammation had little increase in Hb after infusion (3 mg/L) and lower POD 1 Hb (102 mg/L) than either iron-deficient group. Those without iron deficiency showed a decrease in haemoglobin after infusion (−5 mg/L) and lowest POD 1 Hb (95 mg/L).

**Conclusions:** Preoperative intravenous iron is less efficacious in patients with anaemia of inflammation and FID undergoing surgery for CRC, compared with true iron deficiency. Further understanding of the role of perioperative iron infusions is required for maximum gain from therapy.

**Keywords:** Anaemia, Iron, Colorectal cancer, Inflammation
Introduction
Anaemia and perioperative allogeneic blood transfusion are associated with poor outcomes following colorectal cancer (CRC) surgery (Amato and Pescatori 2006). Perioperative optimisation of haemoglobin levels using iron supplementation in iron-deficient patients has been shown to reduce perioperative blood transfusion requirement in colorectal surgery (Froessler et al. 2016). Furthermore, parenteral iron infusions have been shown to improve preoperative haemoglobin levels to a greater degree than oral iron supplements (Keeler et al. 2017). As a result of these observations, our specialist colorectal surgery unit adopted preoperative iron deficiency anaemia identification and iron infusion protocols in 2015 to optimise patient haemoglobin prior to surgery (Quinn et al. 2017).

Although this form of optimisation targets those patients with hypochromic microcytic anaemia of iron deficiency classically associated with gastrointestinal cancers, there is increasing evidence that normocytic anaemia is twice as prevalent (around 20% at diagnosis, compared to 10% with microcytic anaemia) amongst patients diagnosed with colorectal cancer (McSorley et al. 2019a). Patients with normocytic anaemia had higher levels of inflammation as measured by modified Glasgow Prognostic Score (mGPS) (McSorley et al. 2019b). Furthermore, such normocytic anaemia was associated with poorer outcomes following treatment with curative intent (Vayrynen et al. 2018).

It has been proposed that inflammation disturbs hepcidin-mediated red cell iron binding and promotes a ‘functional’ iron deficiency (FID), where despite sufficient stores, iron cannot be utilised for erythropoiesis, leading to anaemia (Kelly et al. 2017). The same mechanisms cause a reduction in enteral iron absorption and sequestration of iron in the reticuloendothelial system, leading to the possibility that any additional iron supplementation given to these patients will not lead to a corresponding change in haemoglobin concentration or red cell count (Nemeth and Ganz 2014).

Therefore, the aim of the present study was to determine if any patients with apparent anaemia of inflammation, or FID, had been treated with preoperative parenteral iron supplementation in our unit and, if so, to determine the impact on haematological parameters. We hypothesised that the presence of inflammation would perturb iron uptake by cells and limit preoperative response to iron infusion. The present study utilised a prospectively collected cohort of primary colorectal cancer patients, given preoperative iron infusions as determined by individual consultants in adherence to unit protocol.

Patients and methods
Patients
Patients with primarily operable colorectal cancer receiving preoperative iron infusion followed by surgery in a single centre between January 2016 and January 2019 were studied. Anonymised clinical pathological data were prospectively recorded in a secure database and subsequently analysed. Patients undergoing surgery for benign disease, with a diagnosed inflammatory disorder or vasculitis, or an underlying haematological malignancy were not included. Patient demographics, along with TNM stage (TNM, 5th ed, AJCC), tumour site, American Society of Anesthesiology (ASA) grade, and surgical approach, were recorded.

All patients were treated by 11 consultant colorectal surgeons in a single institution. All cases were discussed at a specialist colorectal oncology multidisciplinary team meeting, before and after surgery. Each patient was cared for according to unit standardised ERAS protocols and managed by a combination of laparoscopic or open surgery dependent on surgeon preference. Treating surgeons were responsible for identification of anaemia in their patients and determining whether this anaemia required treatment with iron infusion. Treating physicians were encouraged to utilise protocols developed within the unit by surgeons and anaesthetists (Fig. 1).

A waiver of need for ethical approval was granted by the West of Scotland Research Ethics Committee. Caldicott Guardian approval for the collection and analysis of anonymised patient data as part of this project was granted by the office of the Caldicott Guardian for the NHS Greater Glasgow and Clyde region.

Methods
Haematological parameters—full blood count (FBC)-derived haemoglobin and mean corpuscular volume (MCV), ferritin, transferrin saturation (TSAT)—and the biochemical inflammatory parameter C-reactive protein were measured at the time of endoscopic diagnosis and recorded prior to any subsequent parenteral iron infusion, with the purpose of detecting iron deficiency anaemia. Patients were classified as having anaemia based on WHO guidelines for males, haemoglobin (Hb) < 130 mg/L, and females, Hb < 120 mg/L (WHO 2011). Furthermore, anaemic patients were classified as having iron deficiency based on ferritin < 30 μg/L, ferritin 30–100 μg/L with TSAT < 20% or CRP > 5 mg/L, or ferritin > 100 μg/L and transferrin saturation < 20% as shown above (Fig. 1).

Serum concentrations of CRP (mg/L) were measured by the immunoturbidimetric method in the clinical biochemistry laboratory using an autoanayser (Architect; Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L. Ferritin was analysed using a 2-step chemiluminescent microparticle immunoassay in the clinical haematology laboratory. There were no sustained concerns regarding IQC performance requiring investigation into the performance of the assays. The A,
B, and C scores were within the EQA (UK NEQAS) targets during the study period.

Patients had FBC samples taken on the day of surgery and again on postoperative day 1. The change in haemoglobin following iron infusion was calculated by subtracting immediate pre-operative haemoglobin from haemoglobin at presentation.

Patients deemed suitable underwent administration of intravenous ferric carboxymaltose (Ferinject®, Vifor Pharma UK), via peripheral intravenous cannula over 15 min, in the preoperative assessment unit. The dose was dependent on body weight and haemoglobin (Vifor Pharma n.d.), and the aim was to have the first infusion at least 14 days before surgery.

**Statistical analysis**

Patients were grouped by protocol-defined pre-infusion ferritin and CRP cut-off values into those who were truly iron deficient (ferritin < 30 μg/L and CRP ≤ 5 mg/L, n = 18), those with probable FID (ferritin < 30 μg/L and CRP > 5 mg/L, n = 17), those with probable anaemia of inflammation (ferritin ≥ 30 μg/L and CRP > 5 mg/L, n = 6), and those with anaemia of another cause who were given parenteral iron despite no evidence of iron deficiency.
deficiency (ferritin $\geq 30 \mu g/L$ and CRP $\leq 5 mg/L$, $n = 6$). Comparisons were made between categorical clinical and pathological variables using the chi-square test and chi-square test for trend where appropriate. Comparisons were made with pre-infusion haemoglobin, change in haemoglobin, and postoperative day 1 haemoglobin using the Kruskal-Wallis test.

Univariate linear regression was used to examine associations between these variables and change in haemoglobin ($\Delta Hb$ mg/L) following iron infusion. Those variables found to be associated with a significance level of $p < 0.01$ were entered into a multivariate linear regression backward condition model to examine independent associations. Results were reported as the regression coefficient for each variable and their 95% confidence interval (CI).

Two-sided $p$ values $< 0.05$ were considered statistically significant. All analyses were performed using IBM SPSS version 25 (IBM, Chicago, Illinois, USA).

**Results**

**Patients**

Over the study period, 52 patients received an intravenous iron infusion prior to elective surgery for colorectal cancer. Patient demographics and clinical, pathological, and haematological variables are shown in Table 1. The majority were male ($n = 30, 58\%$) and 65 years or older ($n = 43, 83\%$). Laparoscopic resection was performed in 27 (52\%), and 45 (86\%) had colon cancer while the remaining 7 (14\%) had a rectal cancer. All patients were anaemic prior to iron infusion, and of these, 49 had a pre-infusion ferritin measured, 48 had a pre-infusion CRP measured, and 47 had both measured. Thirty-six (74\%) had protocol defined low ferritin while half of the 48 patients who had CRP measured prior to iron infusion had protocol defined systemic inflammation present with a CRP $> 5$ mg/L.

**Iron infusion**

The total dose of iron infused (Table 1) varied between 1000 mg ($n = 19, 36\%$), 1500 mg ($n = 23, 45\%$), and 2000 mg ($n = 11, 19\%$). The median time between infusion and surgery was 24 days (range 1–83). Following infusion, in the cohort as a whole, the median haemoglobin change before surgery was a rise of 12 mg/L (range −15 to 63), with haemoglobin rising above the cut-off for anaemia in 8 patients (15\%).

**Associations between pre-iron infusion iron status and clinicopathological variables**

When patients were grouped by protocol-defined pre-infusion ferritin and CRP cut-off values into those who were truly iron deficient (ferritin $< 30 \mu g/L$ and CRP $\leq 5$ mg/L, $n = 18$), those with probable FID (ferritin $< 30 \mu g/L$ and CRP $> 5$ mg/L, $n = 17$), those with probable anaemia of inflammation (ferritin $\geq 30 \mu g/L$ and CRP $> 5$ mg/L, $n = 6$), and those who were given parenteral iron despite no evidence of iron deficiency (ferritin $\geq 30 \mu g/L$ and CRP $\leq 5$ mg/L, $n = 6$), there was no association between this pre-infusion iron status and sex, age, co-morbidity, or disease stage (Table 2).

Only tumour site was significantly associated with pre-infusion iron status ($p = 0.006$), with all of the rectal cancer patients in the cohort ($n = 7, 39\%$ of all iron deficiency patients) having true iron deficiency, while there was a preponderance to right-sided lesions in the functional iron deficiency ($n = 17, 100\%$), anaemia of inflammation ($n = 5, 83\%$), and non-deficient ($n = 5, 83\%$) groups.

**Associations between pre-infusion iron status and haematological variables**

Those patients (Table 2) who were categorised as truly iron deficient (ferritin $< 30 \mu g/L$ and CRP $\leq 5$ mg/L, $n = 18$) had the lowest median pre-infusion haemoglobin (100 mg/L, range 77 to 118). They had the greatest median increase in haemoglobin between infusion and surgery (24 mg/L, range 6 to 48) and the highest median postoperative day 1 haemoglobin (108 mg/L, range 87 to 133).

Those patients who were categorised as FID (ferritin $< 30 \mu g/L$ and CRP $> 5$ mg/L, $n = 17$) had the second lowest median pre-infusion haemoglobin (102 mg/L, range 65 to 122), the second greatest median increase in haemoglobin between infusion and surgery (15 mg/L, range −15 to 63), and the second highest median postoperative day 1 haemoglobin (103 mg/L, range 87–138).

Those patients who were categorised as having anaemia of inflammation (ferritin $\geq 30 \mu g/L$ and CRP $> 5$ mg/L, $n = 17$) had a higher median pre-infusion haemoglobin than either of the two iron-deficient groups (110 mg/L, range 75 to 117), a lower median increase in haemoglobin between infusion and surgery than either of the two iron-deficient groups (3 mg/L, range −11 to 34), and a lower median postoperative day 1 haemoglobin than either of the two iron-deficient groups (102 mg/L, range 74–113).

Finally, those patients who were categorised as having anaemia of another cause or without evidence of iron deficiency (ferritin $< 30 \mu g/L$ and CRP $\geq 5$ mg/L, $n = 18$) had a similar median pre-infusion haemoglobin to those with anaemia of inflammation (110 mg/L, range 103 to 115). They had a median decrease in haemoglobin between infusion and surgery (−5 mg/L, range −10 to 8) and the lowest median postoperative day 1 haemoglobin (95 mg/L, range 85 to 99). Although this group were not defined as iron deficient by protocol, none were found to be vitamin B12 or folate deficient.
At multivariate linear regression (Table 3), total parenteral iron dose \((p = 0.034)\), time from infusion to surgery \((p < 0.001)\), haemoglobin prior to iron infusion \((p = 0.002)\), and CRP- and ferritin-based iron status group \((p = 0.006)\) all remained independently associated with post iron infusion change in haemoglobin.

**Discussion**

The results of the present study suggest that, in patients with primary operable colorectal cancer found to be anaemic at diagnosis, preoperative iron infusions improved pre- and postoperative haemoglobin in the truly iron deficient, but not those without evidence of iron deficiency. Those patients with low ferritin in the presence of inflammation, consistent with the presence of functional iron deficiency, had an intermediate haemoglobin response to iron infusion. Those with both high ferritin and high CRP, consistent with the presence of anaemia of inflammation, had a negligible haemoglobin response to iron infusion. In addition, a higher dose of iron, a longer time delay between infusion and surgery, and a lower haemoglobin before infusion were associated with greater increases in haemoglobin after iron infusion.

These findings are in-keeping with the hypothesis that in a proportion of anaemic colorectal cancer patients, the host inflammatory response to cancer leads to either a state of functional iron deficiency anaemia or anaemia of inflammation (Tokunaga et al. 2018). It would appear from this small cohort that functional iron deficiency can, to an extent, be improved by parenteral iron supplementation. It may be that in this group, the dose and

### Table 1 Demographic and clinicopathological variables of patients receiving intravenous iron infusions prior to elective colorectal surgery for cancer \((n = 52)\)

| Characteristic                        | n (% ) |
|--------------------------------------|--------|
| Total                                | 52 (100) |
| **Patient characteristics**          |        |
| Sex                                  |        |
| Male                                 | 30 (58) |
| Female                               | 22 (42) |
| Age (years)                          |        |
| < 65                                 | 9 (17)  |
| 65–75                                | 15 (29) |
| > 75                                 | 28 (54) |
| ASA                                  |        |
| 1                                    | 2 (4)   |
| 2                                    | 26 (50) |
| 3                                    | 22 (42) |
| 4                                    | 2 (4)   |
| **Pathologic and surgical characteristics** |    |
| TNM stage                            |        |
| 1                                    | 7 (12)  |
| 2                                    | 24 (47) |
| 3                                    | 18 (35) |
| 4                                    | 3 (6)   |
| Tumour site                          |        |
| Right colon                          | 38 (72) |
| Left colon                           | 7 (14)  |
| Rectum                               | 7 (14)  |
| Approach                              |        |
| Open                                 | 25 (48) |
| Laparoscopic                         | 27 (52) |
| **Haematological variables**         |        |
| Pre-infusion Hb (mg/L)               |        |
| Median (range)                       | 103 (65–123) |
| Pre-infusion anaemia*                |        |
| Yes                                  | 52 (100) |
| No                                   | 0 (0)   |
| Pre-infusion ferritin (μg/L)         |        |
| Median (range)                       | 18 (3–302) |
| < 30                                 | 36 (74) |
| 30–100                               | 7 (14)  |
| > 100                                | 6 (12)  |
| Pre-infusion CRP (mg/L)              |        |
| Median (range)                       | 6 (1–113) |
| ≤ 5                                  | 24 (50) |
| > 5                                  | 24 (50) |

ASA American Society of Anesthesiology, CRP C-reactive protein, IV intravenous

*Pre-iron infusion haemoglobin: males < 130 mg/L, females < 120 mg/L

$Post-iron infusion haemoglobin: males \(\geq 130\) mg/L, females \(\geq 120\) mg/L

### Table 1 Demographic and clinicopathological variables of patients receiving intravenous iron infusions prior to elective colorectal surgery for cancer \((n = 52)\) (Continued)

| Characteristic                        | n (% ) |
|--------------------------------------|--------|
| Total IV iron dose (mg)              |        |
| 1000                                 | 17 (36) |
| 1500                                 | 21 (45) |
| 2000                                 | 9 (19)  |
| Days from infusion to surgery        |        |
| Median (range)                       | 24 (1–83) |
| Haematological outcomes              |        |
| Post-infusion change \((\Delta)\) in Hb (mg/L) |        |
| Median (range)                       | 12 (– 15 to 63) |
| Anaemia ‘corrected’$                |        |
| Yes                                  | 8 (15)  |
| No                                   | 44 (85) |

At multivariate linear regression (Table 3), total parenteral iron dose \((p = 0.034)\), time from infusion to surgery \((p < 0.001)\), haemoglobin prior to iron infusion \((p = 0.002)\), and CRP- and ferritin-based iron status group \((p = 0.006)\) all remained independently associated with post iron infusion change in haemoglobin.

ASA American Society of Anesthesiology, CRP C-reactive protein, IV intravenous

*Pre-iron infusion haemoglobin: males < 130 mg/L, females < 120 mg/L

$Post-iron infusion haemoglobin: males ≥ 130 mg/L, females ≥ 120 mg/L

**Associations with post-iron infusion change in haemoglobin**

At multivariate linear regression (Table 3), total parenteral iron dose \((p = 0.034)\), time from infusion to surgery \((p < 0.001)\), haemoglobin prior to iron infusion \((p = 0.002)\), and CRP- and ferritin-based iron status group \((p = 0.006)\) all remained independently associated with post iron infusion change in haemoglobin.
Table 2 Clinicopathological and haematological factors associated with protocol-defined iron status prior to intravenous iron infusion for elective colorectal surgery for cancer (n = 47)

| Characteristic | Pre-infusion iron status |  |  |  | p  |
|---------------|-------------------------|---|---|---|---|
|               | (CRP ≤ 5 + Fer < 30) n (%) | (CRP > 5 + Fer < 30) n (%) | (CRP > 5 + Fer ≥ 30) n (%) | (CRP ≤ 5 + Fer ≥ 30) n (%) |   |
| Total         | 18 (38)                 | 17 (38)                 | 6 (12)                 | 6 (12)                 | –  |
| Patient characteristics |                     |                      |                          |                          |   |
| Sex           |                          |                          |                          |                          |   |
| Male          | 13 (72)                  | 10 (59)                 | 1 (17)                  | 3 (50)                  | 0.120 |
| Female        | 5 (28)                   | 7 (41)                  | 5 (83)                  | 3 (50)                  |   |
| Age (years)   |                          |                          |                          |                          |   |
| < 65          | 1 (6)                    | 5 (29)                  | 1 (17)                  | 1 (17)                  | 0.261 |
| 65–75         | 6 (33)                   | 2 (12)                  | 3 (50)                  | 3 (50)                  |   |
| > 75          | 11 (61)                  | 10 (59)                 | 2 (33)                  | 2 (33)                  |   |
| ASA           |                          |                          |                          |                          |   |
| 1             | 0 (0)                    | 2 (12)                  | 0 (0)                   | 0 (0)                   | 0.070 |
| 2             | 9 (50)                   | 3 (17)                  | 6 (100)                 | 4 (67)                  |   |
| 3             | 8 (44)                   | 11 (65)                 | 0 (0)                   | 2 (33)                  |   |
| 4             | 1 (6)                    | 1 (6)                   | 0 (0)                   | 0 (0)                   |   |
| Pathologic characteristics |                     |                      |                          |                          |   |
| TNM stage     |                          |                          |                          |                          | 0.448 |
| 1             | 1 (6)                    | 3 (18)                  | 0 (0)                   | 2 (33)                  |   |
| 2             | 11 (61)                  | 5 (29)                  | 3 (50)                  | 3 (50)                  |   |
| 3             | 6 (33)                   | 8 (47)                  | 3 (50)                  | 1 (17)                  |   |
| 4             | 0 (0)                    | 1 (6)                   | 0 (0)                   | 0 (0)                   |   |
| Tumour site   |                          |                          |                          |                          | 0.006 |
| Right colon   | 8 (44)                   | 17 (100)                | 5 (83)                  | 5 (83)                  |   |
| Left colon    | 3 (17)                   | 0 (0)                   | 1 (17)                  | 1 (17)                  |   |
| Rectum        | 7 (39)                   | 0 (0)                   | 0 (0)                   | 0 (0)                   |   |
| Infusion variables |                     |                      |                          |                          |   |
| Total IV iron dose (mg) |           |                      |                          |                          |   |
| 1000          | 7 (44)                   | 6 (40)                  | 0 (0)                   | 3 (50)                  | 0.254 |
| 1500          | 4 (25)                   | 7 (47)                  | 4 (67)                  | 3 (50)                  |   |
| 2000          | 5 (31)                   | 2 (13)                  | 2 (33)                  | 0 (0)                   |   |
| Days from infusion to surgery |         |                      |                          |                          | 0.233 |
| Median (range) | 20 (3–83)                | 30 (7–62)               | 25 (19–44)              | 16 (2–48)               |   |
| Haematological variables |                  |                      |                          |                          |   |
| Pre-iron Hb (mg/L) |             |                      |                          |                          |   |
| Median (range) | 100 (77–118)             | 102 (65–122)            | 110 (75–117)            | 110 (103–115)           | 0.101 |
| Δ Hb (mg/L)   |                          | 24 (–6 to 48)          | 15 (–15 to 63)          | 3 (–11 to 34)           | – 5 (–10 to 8)          | 0.017 |
| POD1 Hb (mg/L) |                         | 108 (87–133)           | 103 (87–138)            | 102 (74–113)            | 95 (85–99)              | 0.028 |

AOI: anaemia of inflammation, ASA: American Society of Anesthesiology, CRP: C-reactive protein (mg/L), Fer: ferritin (μg/L), FID: functional iron deficiency, Hb: haemoglobin (g/L), IDA: iron deficiency anaemia, IV: intravenous, POD: postoperative day
The parenteral route of iron supplementation overcomes hepcidin-mediated iron sequestration and inhibition of absorption of dietary iron; however, this does not fully explain the lesser response to iron seen in patients with high levels of inflammation (Munoz et al. 2011). Although previous studies have noted success in the correction of preoperative anaemia with oral iron in true iron deficiency (Lidder et al. 2007), it is less clear whether oral supplementation is of use in the FID group.

Conversely, those patients with haematological and biochemical measures consistent with anaemia of inflammation (normal ferritin, raised CRP) appear to have anaemia which is resistant to correction by iron infusion as it is likely caused by other factors. The prevalence of this condition in colorectal cancer must be recognised and clinicians should be cogniscente of this when determining how to optimise their patients in the perioperative period. Preoperative systemic inflammation has been reported to be associated with co-morbidity, postoperative complications, and poorer long-term survival in patients with colorectal cancer, and it may be that preoperative anaemia is an important and related factor (Dolan et al. 2018).

Allogeneic blood transfusions have been associated with increased postoperative infective complications, increased disease recurrence, and poorer survival following surgery for colorectal cancer (Acheson et al. 2012; Pang et al. 2019). Although the mechanism is not fully understood, one key hypothesis is that allogenic blood causes host adaptive immune suppression (Blumberg and Heal 1994), even when using modern leucodepleted packed red cells (Mynster et al. 2000). Therefore, current trends in perioperative medicine and blood management strategies aim to reduce the need for perioperative allogeneic blood transfusion, with preoperative iron supplementation forming a key strategy (Ng et al. 2015). Parenteral iron is not without potential for harm, being associated with a small risk of anaphylaxis. In addition, there is now some evidence that excess iron may be associated with negative oncologic outcomes (Xue et al. 2016; Greten 2016; Radulescu et al. 2012). It is possible that such an effect may be compounded in patients with an existing host systemic inflammatory response, although further studies are required to examine this matter. In attempting to reduce perioperative transfusion, there is evidence from this study, unsurprisingly, that the best haemoglobin response to parenteral iron replacement is in those with true iron deficiency. Further strategies preventing and addressing other causes of anaemia in colorectal cancer are required. This can only be achieved by better understanding of the causes of anaemia in this patient group. It is possible that treatment of inflammation may release checks on erythropoiesis and should be the subject of further study.

It was of interest that tumour site appeared to have an impact on pre-iron infusion iron status defined by CRP and ferritin in this protocol. Almost all patients grouped as having functional iron deficiency and anaemia of inflammation had right colonic lesions, as opposed to the significant proportion of patients with rectal cancer in the true iron-deficient group. The link between right colonic tumours and the presence of both local and systemic inflammation has been documented previously (Patel et al. 2018), as has the association between right colonic tumours and normocytic anaemia (Vayrynen et al. 2018). Therefore, the host interaction with these proximal colonic lesions seems to drive systemic inflammatory driven changes in iron and erythrocytes.

This study has a number of limitations. The number of patients is small, increasing the risk of type 2 error. No data was available regarding patients who had received oral iron supplementation in either primary or secondary care before diagnosis or surgery, increasing the possibility of selection bias and preventing a useful

### Table 3

| Characteristic                      | Univariate regression coefficient (95% CI) | p       | Multivariate regression coefficient (95% CI) | p       |
|-------------------------------------|-------------------------------------------|---------|---------------------------------------------|---------|
| Male sex                            | −7.7 (−17.3 to 1.9)                       | 0.112   | −                                           | −       |
| Age                                 | 4.7 (−1.6 to 10.9)                        | 0.140   | −                                           | −       |
| ASA                                 | 2.0 (−5.6 to 9.7)                         | 0.594   | −                                           | −       |
| TNM stage                           | 8.2 (2.2–14.2)                            | 0.008   | −                                           | 0.780   |
| Tumour site                         | 1.8 (−4.9 to 8.6)                         | 0.590   | −                                           | −       |
| Total iron dose (mg)                | 0.02 (0.01–0.03)                          | 0.003   | 0.01 (0.0–0.2)                              | 0.034   |
| Days from infusion to surgery       | 0.5 (0.3–0.7)                             | <0.001  | 0.4 (0.2–0.6)                               | <0.001  |
| Pre-iron infusion Hb (mg/L)         | −0.8 (−1.1 to −0.6)                       | <0.001  | −0.5 (−0.7 to −0.2)                         | 0.002   |
| Pre-iron infusion CRP and ferritin  | −6.9 (−11.50 to −2.19)                    | 0.005   | −4.7 (−7.9 to −1.47)                        | 0.006   |

AOI: anaemia of inflammation, ASA: American Society of Anesthesiology, CRP: C-reactive protein (mg/L), Fer: ferritin (μg/L), FID: functional iron deficiency, Hb: haemoglobin (g/L), IDA: iron deficiency anaemia, IV: intravenous, POD: postoperative day
comparison between different routes of iron supplementation in patients with functional iron deficiency or anaemia of inflammation. Furthermore, there were no data examining patients with functional iron deficiency or anaemia of inflammation who did not receive a preoperative iron infusion. In addition, a number of patients who were anaemic but without evidence of inflammation or iron deficiency received an iron infusion, against the unit protocol. Again, this could suggest selection bias, but in terms of an observational study, provided an additional interesting group of patients for comparison in a real-world study, with findings confirming they fail to respond to iron infusion as hypothesised. Although data did exist relating to perioperative blood transfusion in this cohort, the lack of an established transfusion protocol meant that this was not included in the analysis. Finally, there was no reliable recording of estimated operative blood loss in the cohort, which may lead to bias with regard to the analysis of postoperative haemoglobin.

In summary, this observational study reports a reduced efficacy of preoperative parenteral iron supplementation in patients thought to have anaemia of inflammation, and to a lesser extent functional iron deficiency, in patients undergoing surgery for colorectal cancer, compared with those who were truly iron deficient. This study illustrates that iron infusion is of greatest benefit to the truly iron-deficient patient in the absence of preoperative inflammation. Given that the presence of anaemia and inflammation are in fact much more common in the preoperative colorectal cancer population than iron deficiency anaemia alone, these results suggest that this area requires further focused study. It may be that alternative preoperative haemoglobin optimisation methods, for example targeting the underlying host inflammatory response to cancer, may prove to be of more use in these groups of patients than targeting all patients with low ferritin levels with preoperative iron infusions.

Abbreviations
AJCC: American Joint Committee on Cancer; ASA: American Society of Anesthesiology; AoI: Anaemia of inflammation; CI: Confidence interval; CNS: Cancer nurse specialist; CRC: Colorectal cancer; CRP: C-reactive protein; EPO: Erythropoietin; EQA: External quality assurance; ERAS: Enhanced recovery after surgery; F: Female; FBC: Full blood count; FID: Functional iron deficiency; GP: General practitioner; Hb: Haemoglobin; IDA: Iron deficiency anaemia; IQC: Internal quality control; IV: Intravenous; M: Male; MCV: Mean corpuscular volume; mGPS: Modified Glasgow Prognostic Score; POD: postoperative day; SDAU: Same day admission unit; TNM: Tumour nodes metastasis staging; TSAT: Transferrin saturation; WHO: World Health Organization

Acknowledgements
The authors thank Ms Edel Quinn, surgical registrar, who was heavily involved in the original development of the local preoperative iron infusion protocol. The authors thank lead pharmacist Ellen Meland for her work instituting this perioperative treatment regimen. Finally, the authors would like to thank the surgeons, nursing staff, and patients of the Glasgow Royal Infirmary Department of Coloproctology.

This research was not pre-registered in an institutional registry.

Authors' contributions
Study conception and design: STM, JHA, DCM, CWS. Acquisition of data: STM, TW, CWS. Analysis and interpretation of data: STM, TW, CWS, DCM. Drafting of the manuscript: STM, CSDR, PGH, DCM, CWS. Critical revision of the manuscript: STM, JHA, CSDR, PGH, DCM, CWS. The authors read and approved the final manuscript.

Funding
None

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to the small number of patients included and therefore the possibility that a patient may be identified even from otherwise anonymised data. Limited data are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved with the need for individual patient consent waived by the West of Scotland research ethics committee due to its retrospective observational nature.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests

Received: 2 December 2019 Accepted: 1 May 2020
Published online: 11 June 2020

References
Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery. Ann Surg. 2012;256:235–44.
Amato A, Pescatori M. Perioperative blood transfusion for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;25(1):CD005033.
Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med. 1994;118(4):371–9.
Dolan RD, McSorley ST, Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018;119(1):40–51.
Froessler B, Palm P, Weber I, Hodyl N, Singh R, Murphy E. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg. 2016;264(1):41–6.
Greten FR. The irony of tumour-induced inflammation. Cell Metabolism. 2016;24: 368–9.
Keefer BD, Simpson JA, Ng O, Padmanabhan H, Brookes MJ, Acheson AG, MICA Trial Group. Randomized clinical trial of perioperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br J Surg. 2017;104(3):214–21.
Kelly AU, McSorley ST, Patel P, Talwar D. Interpreting iron studies. BMJ. 2017;357: j2513.
Liddar PG, Sanders G, Whitehead E, Douie WJ, Mellor N, Lewis SJ, Hosie KB. Preoperative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Ann R Coll Surg Engl. 2007;89(4):418–21.
McSorley ST, Johnstone M, Steele CW, Roxburgh CS, Horgan PG, McMillan DC, Mansouri D. Normocytic anaemia is associated with systemic inflammation and poorer survival in patients with colorectal cancer treated with curative intent. Int J Colorectal Dis. 2019a;34(3):401–8.
McSorley ST, Tham A, Steele CW, Dolan RD, Roxburgh CS, Horgan PG, McMillan DC. Quantitative data on red cell measures of iron status and their relation to the magnitude of the systemic inflammatory response and survival in patients with colorectal cancer. Eur J Surg Oncol. 2019b;45(7):1205–11.
Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part I: molecular basis of iron homeostasis. J Clin Pathol. 2011;64:281–6.
Mynster T, Christensen U, Moesgaard F, et al. for the Danish RANX05 Colorectal Cancer Study Group. Effects of the combination of blood transfusion and
postoperative infectious complications on prognosis after surgery for colorectal cancer. Br J Surg. 2000;87:1553–62.

Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am. 2014;28(4):671–81.

Ng Q, Keeler BD, Mishra A, Simpson A, Neal K, Brookes MJ, Acheson AG. Iron therapy for pre-operative anaemia. Cochrane Database Syst Rev. 2015;(2):CD001588.

Pang QY, An R, Liu HL. Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis. World J Surg Oncol. 2019;17(1):7. https://doi.org/10.1186/s12957-018-1551-y.

Patel M, McSorley ST, Park JH, Roxburgh CSD, Edwards J, Horgan PG, McMillan DC. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. Br J Cancer. 2018;118(5):705–12.

Quinn EM, Meland E, McGinn S, Anderson JH. Correction of iron-deficiency anaemia in colorectal surgery reduces perioperative transfusion rates: a before and after study. Int J Surg. 2017;38:1–8.

Radulescu S, Brookes MJ, Salgueiro P, Ridgway RA, McGhee E, Anderson K, et al. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep. 2012;2(2):270–82.

Tokunaga R, Nakagawa S, Miyamoto Y, Ohuchi M, Isumi D, Kosumi K, Taki K, Higashi T, Miyata T, Yoshida N, Baba H. The impact of preoperative anaemia and anaemic subtype on patient outcome in colorectal cancer. Colorectal Dis. 2018. https://doi.org/10.1111/cod.14425.

Vayrynen JP, Tuomisto A, Vayrynen SA, Klintrup K, Karhu K, Makela J, Herzig KH, Karttunen TJ, Makinen MJ. Preoperative anaemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival. Sci Rep. 2018;8:1126.

Vifor Pharma. Ferinject® Summary of Product Characteristics. (n.d.)Available at http://www.medicines.org.uk/emc/medicine/24167/SPC Date of revision of the text October 2013.

WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutritional Information System. Geneva: World Health Organization; 2011. (WHO/NMH/NHD/MNM/11.1).

Xue X, Ramakrishnan SK, Weisz K, Triner D, Xie L, Attili A, Pant A, Gyóffy B, Zhan M, Carter-Su C, Hardiman KM, Wang TD, Darke MK, Varani J, Brenner D, Fearon ER, Shah YM. Iron uptake via DMT1 integrates cell cycle with JAK-STAT3 signalling to promote colorectal tumorigenesis. Cell Metabolism. 2016;24(3):447–61.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.